Literature DB >> 33748947

The global, regional, and national burden of gallbladder and biliary tract cancer and its attributable risk factors in 195 countries and territories, 1990 to 2017: A systematic analysis for the Global Burden of Disease Study 2017.

Guoqing Ouyang1, Qiang Liu1, Yongrong Wu1, Zhen Liu1, Wuchang Lu1, Shuai Li1, Guangdong Pan1, Xiang Chen2,3.   

Abstract

BACKGROUND: The global burden of gallbladder and biliary tract cancer (GBTC) is increasing. A comprehensive evaluation of the burden is crucial to improve strategies for GBTC prevention and treatment.
METHODS: The incidence rates, mortality, and disability-adjusted life years (DALYs) of GBTC from 1990 to 2017 were extracted from the Global Burden of Diseases Study (GBD) 2017. Estimated annual percent changes (EAPCs) were calculated to quantify GBTC trends during the study period.
RESULTS: Globally, there were 210,878 new cases, 173,974 deaths, and 3,483,046 DALYs because of GBTC in 2017. GBTC incidence increased by 76%, mortality increased by 65%, and DALYs increased by 52% from 1990 to 2017. In addition, relatively higher Socio-Demographic Index regions had greater incidence and death rates but greatly decreased age-standardized incidence rate (ASIR) and age-standardized death rate (ASDR). At the national level, Chile had the highest ASIR (10.38 per 100,000 population) and the highest ASDR (10.43 per 100,000 population) in 2017. The largest increases in ASIR (EAPC, 3.38) and ASDR (EAPC, 3.39) were observed in Georgia. Nonlinear associations were observed between the ASDR, the Socio-Demographic Index, and DALYs at the 21 GBD regional levels and at the national level. The proportions of GBTC age-standardized deaths and DALYs attributable to high body mass index were 15.4% and 16%, respectively.
CONCLUSIONS: GBTC remains a major health burden worldwide. These findings are expected to prompt policymakers to establish a cost-effective method for the early diagnosis, prevention, and treatment of GBTC, reducing its modifiable risk factors and reversing its increasing trends. LAY
SUMMARY: Although the rates of age-standardized incidence, death, and disability-adjusted life-years for gallbladder and biliary tract cancer decreased from 1990 to 2017, the numbers of these measures increased. Nonlinear associations existed between the age-standardized death rate, the Socio-Demographic Index, and disability-adjusted life-years at the 21 regional and national levels in the Global Burden of Disease Study.
© 2021 American Cancer Society.

Entities:  

Keywords:  Global Burden of Diseases Study; death; disability-adjusted life-years; estimated annual percent changes; gallbladder and biliary tract cancer; incidence

Mesh:

Year:  2021        PMID: 33748947     DOI: 10.1002/cncr.33476

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  6 in total

1.  Comprehensive Analysis of the Potential Immune-Related Biomarker ATG101 that Regulates Apoptosis of Cholangiocarcinoma Cells After Photodynamic Therapy.

Authors:  Zi-Jian Zhang; Kun-Peng Wang; Yun-Peng Huang; Chong Jin; Hao Jiang; Li Xiong; Zhao-Yi Chen; Yu Wen; Zhong-Tao Liu; Jing-Gang Mo
Journal:  Front Pharmacol       Date:  2022-05-03       Impact factor: 5.988

Review 2.  Changing Landscape of Systemic Therapy in Biliary Tract Cancer.

Authors:  Edward Woods; Dat Le; Bharath Kumar Jakka; Ashish Manne
Journal:  Cancers (Basel)       Date:  2022-04-25       Impact factor: 6.575

Review 3.  First report of a gallbladder hemangioma coexisting with gallstones: a case report and literature review of a rare finding.

Authors:  Giulia Trucco; Luigi Chiusa; Francesco Tandoi; Luca Bertero
Journal:  BMC Surg       Date:  2022-04-06       Impact factor: 2.102

4.  Chinese and Global Burdens of Gastrointestinal Cancers From 1990 to 2019.

Authors:  Wangcheng Xie; Tingsong Yang; Jieliang Zuo; Zhilong Ma; Weidi Yu; Zhengyu Hu; Zhenshun Song
Journal:  Front Public Health       Date:  2022-07-13

5.  PI3K/AKT phosphorylation activates ERRα by upregulating PGC‑1α and PGC‑1β in gallbladder cancer.

Authors:  Lei Wang; Mengmeng Yang; Huihan Jin
Journal:  Mol Med Rep       Date:  2021-06-29       Impact factor: 2.952

6.  Case Report: Addition of PD-1 Antibody Camrelizumab Overcame Resistance to Trastuzumab Plus Chemotherapy in a HER2-Positive, Metastatic Gallbladder Cancer Patient.

Authors:  Li Wang; Xiaomo Li; Yurong Cheng; Jing Yang; Si Liu; Tonghui Ma; Li Luo; Yanping Hu; Yi Cai; Dong Yan
Journal:  Front Immunol       Date:  2022-01-06       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.